AGL Rockets 169% as Healthcare Revisions Sweep Top Movers

AGL shares surged after the company reported Q1 2026 adjusted EPS of $1.80, beating the $1.13 analyst consensus by 59%, with revenue of $1.42 billion exceeding the $1.38 billion estimate.

The rally pushed shares to $71.96, but with Q1 EPS beating by 59% and full-year revenue guidance reaffirmed at $5.68–$5.81 billion, the stock may have room if earnings momentum continues.

The May 6, 2026 earnings release triggered AGL's best day ever as net income of $2.94 per share and adjusted EPS of $1.80 significantly exceeded expectations, driving a 75% single-day gain.

ERNA surged 75.3% after its forward EPS growth estimate reached 87.4%, signaling analyst expectations for substantial earnings expansion as the company advances its clinical pipeline.

With an 87.4% forward EPS growth estimate and no recent earnings news to explain the move, investors should verify pipeline catalysts before deciding on positioning.

ERNA's surge reflects upward revision in analyst EPS growth targets to 87.4%, suggesting expectations for clinical milestones or partnership developments in its oncology programs.

AAOI shares surged 52.8% after its forward EPS growth estimate was revised upward by 49.4pp to 441.7%, with a Mediacom partnership for DOCSIS 4.0 upgrades serving as a validating catalyst.

At $227.50 with a 441.7% EPS growth estimate, AAOI reflects high expectations tied to DOCSIS 4.0 deployments and AI datacenter networking demand—investors should weigh valuation against execution risk.

AAOI's rally was fueled by a 49.4pp EPS revision combined with its selection as Mediacom's primary vendor for upgrades to 1 million homes, validating revenue upside from cable broadband expansion.

NRGV shares gained 34.2% after the company reported a record $1.35 billion backlog and reaffirmed guidance, with management shifting the business model toward recurring-revenue independent power production.

The May 6 call showed a path to an EBITDA run rate exceeding $180 million as backlog assets move into operation, but NRGV trades near $5.65 and investors should monitor execution on the backend-loaded delivery schedule.

NRGV's move was driven by analyst adoption of its strategic pivot from project-based EPC to an IPP model with 60–80% gross margins and 1+ gigawatt of storage capacity under management.

LQDA shares climbed 33.8% after reporting Q1 2026 adjusted EPS of $0.52, beating the $0.37 consensus by 41%, with YUTREPIA sales driving $132.9 million in total revenue versus the $116.6 million estimate.

With YUTREPIA exceeding a $500 million annualized run rate in under a year and management targeting $1 billion revenue by 2027, LQDA at $56.58 may have further upside if physician adoption continues.

LQDA's rally was sparked by its Q1 2026 earnings beat, with a 44% sequential revenue jump and third consecutive profitable quarter reinforcing the commercial trajectory of its pulmonary hypertension therapy.